{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:59:45Z","timestamp":1792803585310,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T00:00:00Z","timestamp":1740873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.trre.2025.100913","type":"journal-article","created":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T23:16:03Z","timestamp":1740957363000},"page":"100913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Transition from preclinical to clinical application of CTLA4-Ig co-stimulation blockage in beta-cell replacement therapy"],"prefix":"10.1016","volume":"39","author":[{"given":"Quentin","family":"Perrier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Noble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Lablanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2025.100913_bb0005","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.diabet.2018.07.006","volume":"45","author":"Wojtusciszyn","year":"2019","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.trre.2025.100913_bb0010","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/ajt.13458","article-title":"Long-term follow-up of the Edmonton protocol of islet transplantation in the United States","volume":"16","author":"Brennan","year":"2016","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"10.1016\/j.trre.2025.100913_bb0015","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.2337\/dc19-0401","article-title":"Ten-year outcome of islet alone or islet after kidney transplantation in type 1 diabetes: a prospective parallel-arm cohort study","volume":"42","author":"Vantyghem","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.trre.2025.100913_bb0020","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1111\/ajt.16637","article-title":"Ten-year outcomes of islet transplantation in patients with type 1 diabetes: data from the Swiss-French GRAGIL network","volume":"21","author":"Lablanche","year":"2021","journal-title":"Am J Transplant Off J Am Soc Transplant Am Soc Transplant Surg"},{"key":"10.1016\/j.trre.2025.100913_bb0025","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/SLA.0000000000005783","article-title":"Pancreas and islet transplantation: comparative outcome analysis of a single-centre cohort over 20-years","volume":"277","author":"Marfil-Garza","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.trre.2025.100913_bb0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S2213-8587(22)00114-0","article-title":"Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-Centre cohort in Canada","volume":"10","author":"Marfil-Garza","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.trre.2025.100913_bb0035","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1432-2277.2008.00640.x","article-title":"Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation","volume":"21","author":"Roland","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2025.100913_bb0040","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1056\/NEJMoa050085","article-title":"Costimulation blockade with Belatacept in renal transplantation","volume":"353","author":"Vincenti","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2025.100913_bb0045","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/1744666X.2019.1574570","article-title":"Belatacept in kidney transplantation and its limitations","volume":"15","author":"Noble","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1016\/j.trre.2025.100913_bb0050","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1600-6143.2010.03016.x","article-title":"A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)","volume":"10","author":"Durrbach","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0055","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2025.100913_bb0060","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0065","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from Calcineurin inhibitor- to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J Am Soc Nephrol JASN"},{"key":"10.1016\/j.trre.2025.100913_bb0070","article-title":"Belatacept for kidney transplant recipients","volume":"2014","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2025.100913_bb0075","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000000964","article-title":"Late conversion from Calcineurin inhibitors to Belatacept in kidney-transplant recipients has a significant beneficial impact on glycemic parameters","volume":"6","author":"Terrec","year":"2020","journal-title":"Transplant Direct"},{"key":"10.1016\/j.trre.2025.100913_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241246577","article-title":"From the clinical to the bench: exploring the insulin modulation effects of tacrolimus and Belatacept","volume":"33","author":"Perrier","year":"2024","journal-title":"Cell Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0085","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1097\/TP.0000000000002048","article-title":"Effect of conversion to CTLA4Ig on tacrolimus-induced diabetic rats","volume":"102","author":"Jin","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0090","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/TP.0000000000002291","article-title":"Belatacept in solid organ transplant: review of current literature across transplant types","volume":"102","author":"Perez","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0095","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1097\/00007890-199704150-00019","article-title":"Expression of CTLA4-Ig by biolistically transfected mouse islets promotes islet allograft survival","volume":"63","author":"Gainer","year":"1997","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0100","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/00007890-199807270-00009","article-title":"Improved survival of biolistically transfected mouse islet allografts expressing CTLA4-Ig or soluble Fas ligand","volume":"66","author":"Gainer","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0105","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00125-002-0844-3","article-title":"Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion","volume":"45","author":"Kimura","year":"2002","journal-title":"Diabetologia"},{"key":"10.1016\/j.trre.2025.100913_bb0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.trim.2004.04.004","article-title":"Transplantation of islets transduced with CTLA4-Ig and TGFbeta using adenovirus and lentivirus vectors","volume":"13","author":"Fernandes","year":"2004","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2025.100913_bb0115","doi-asserted-by":"crossref","first-page":"3283","DOI":"10.1016\/j.transproceed.2006.10.089","article-title":"Enhancing engraftment of neonatal porcine xenoislet with CTLA4Ig and nordihydroguaiaretic acid","volume":"38","author":"Fu","year":"2006","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100913_bb0120","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/TP.0b013e3181f54728","article-title":"In situ protection against islet allograft rejection by CTLA4Ig transduction","volume":"90","author":"Londrigan","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1399-3089.2011.00627.x","article-title":"Porcine CTLA4-Ig prolong islet xenografts in rats by downregulating the direct pathway of T-cell activation","volume":"18","author":"Zhai","year":"2011","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0130","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1016\/j.transproceed.2005.10.117","article-title":"Blockade of both CD28\/B7 and OX40\/OX40L co-stimulatory signal pathways prolongs the survival of islet xenografts","volume":"37","author":"Wang","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100913_bb0135","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1016\/j.transproceed.2007.09.025","article-title":"Prolongation of islet allograft survival by coexpression of CTLA4Ig and CD40LIg in mice","volume":"39","author":"Li","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100913_bb0140","first-page":"3106","article-title":"Inhibition of rejection in murine islet xenografts by CTLA4Ig and CD40LIg gene transfer","volume":"123","author":"Zhang","year":"2010","journal-title":"Chin Med J"},{"key":"10.1016\/j.trre.2025.100913_bb0145","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.transproceed.2010.01.065","article-title":"Effects of gene transfer CTLA4Ig and anti-CD40L monoclonal antibody on islet xenograft rejection in mice","volume":"42","author":"Zhang","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100913_bb0150","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/00007890-200004150-00039","article-title":"A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival","volume":"69","author":"O\u2019Rourke","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0155","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.trim.2008.05.005","article-title":"CTLA4-Ig-modified dendritic cells inhibit lymphocyte-mediated alloimmune responses and prolong the islet graft survival in mice","volume":"19","author":"Yang","year":"2008","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2025.100913_bb0160","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.2337\/dbi20-0047","article-title":"Applying CRISPR screen in diabetes research","volume":"70","author":"Yi","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2025.100913_bb0165","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.2337\/db23-0445","article-title":"Establishment of pancreatic \u03b2-cell\u2013specific gene knockout system based on CRISPR-Cas9 technology with AAV8-mediated gRNA delivery","volume":"72","author":"Ueki","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2025.100913_bb0170","first-page":"1165","article-title":"Ex vivo coating of islet cell allografts with murine CTLA4\/fc promotes graft tolerance","volume":"155","author":"Steurer","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.trre.2025.100913_bb0175","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.2337\/db16-0320","article-title":"Biopatterned CTLA4\/fc matrices facilitate local immunomodulation, engraftment, and glucose homeostasis after pancreatic islet transplantation","volume":"65","author":"Zhang","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2025.100913_bb0180","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ajt.2023.01.007","article-title":"Localized cytotoxic T cell-associated antigen 4 and antioxidant islet encapsulation alters macrophage signaling and induces regulatory and anergic T cells to enhance allograft survival","volume":"23","author":"Barra","year":"2023","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0185","doi-asserted-by":"crossref","first-page":"695","DOI":"10.3727\/000000002783985413","article-title":"Proliferative and cytokine responses in CTLA4-Ig-treated diabetic NOD mice transplanted with microencapsulated neonatal porcine ICCs","volume":"11","author":"Safley","year":"2002","journal-title":"Cell Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0190","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.tp.0000255592.09784.ba","article-title":"Blockade of the passive cell death pathway does not prevent tolerance induction to islet grafts","volume":"83","author":"Lehnert","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0195","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/xen.12086","article-title":"Encapsulated piscine (tilapia) islets for diabetes therapy: studies in diabetic NOD and NOD-SCID mice","volume":"21","author":"Safley","year":"2014","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0200","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/TP.0000000000001482","article-title":"In vivo Costimulation blockade-induced regulatory T cells demonstrate dominant and specific tolerance to porcine islet xenografts","volume":"101","author":"Wu","year":"2017","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0205","doi-asserted-by":"crossref","DOI":"10.1111\/xen.12577","article-title":"Multiple clinically relevant immunotherapies prolong the function of microencapsulated porcine islet xenografts in diabetic NOD mice without the use of anti-CD154 mAb","volume":"27","author":"Safley","year":"2020","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0210","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-3083.2006.01836.x","article-title":"Combined costimulation blockade prevents rejection of allogeneic islets in mice","volume":"64","author":"Malm","year":"2006","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.trre.2025.100913_bb0215","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1097\/01.tp.0000261722.02697.75","article-title":"Anti-LFA-1 improves pig islet xenograft function in diabetic mice when long-term acceptance is induced by CTLA4Ig\/anti-CD40L","volume":"83","author":"Kumagai-Braesch","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0220","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.transproceed.2010.05.084","article-title":"Effect of triple costimulation blockade on islet allograft survival in sensitized mice","volume":"42","author":"Diab","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2025.100913_bb0225","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1097\/01.TP.0000144054.46946.CF","article-title":"Beneficial effects of costimulatory blockade with anti-inducible costimulator antibody in conjunction with CTLA4Ig on prevention of islet xenograft rejection from rat to mouse","volume":"78","author":"Nabeyama","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0230","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/ajt.12838","article-title":"The combination of anti-NKG2D and CTLA-4 Ig therapy prolongs islet allograft survival in a murine model","volume":"14","author":"Pawlick","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0235","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4161\/isl.21239","article-title":"Blockade of both B7-H4 and CTLA-4 co-signaling pathways enhances mouse islet allograft survival","volume":"4","author":"Wang","year":"2012","journal-title":"Islets"},{"key":"10.1016\/j.trre.2025.100913_bb0240","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/01.tp.0000280545.14489.df","article-title":"Blockade of LIGHT\/HVEM and B7\/CD28 signaling facilitates long-term islet graft survival with development of allospecific tolerance","volume":"84","author":"Fan","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0245","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2337\/db09-0502","article-title":"Caspase inhibitor therapy synergizes with costimulation blockade to promote indefinite islet allograft survival","volume":"59","author":"Emamaullee","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2025.100913_bb0250","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.2337\/db09-1264","article-title":"A novel clinically relevant strategy to abrogate autoimmunity and regulate alloimmunity in NOD mice","volume":"59","author":"Vergani","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2025.100913_bb0255","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1111\/j.1600-6143.2007.01996.x","article-title":"Combined coinhibitory and costimulatory modulation with anti-BTLA and CTLA4Ig facilitates tolerance in murine islet allografts","volume":"7","author":"Truong","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0260","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1097\/01.tp.0000289995.70390.20","article-title":"Negative and positive co-signaling with anti-BTLA (PJ196) and CTLA4Ig prolongs islet allograft survival","volume":"84","author":"Truong","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0265","first-page":"5187","article-title":"Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation","volume":"159","author":"Levisetti","year":"1950","journal-title":"J Immunol Baltim Md"},{"key":"10.1016\/j.trre.2025.100913_bb0270","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2337\/diabetes.51.2.265","article-title":"Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates","volume":"51","author":"Adams","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.trre.2025.100913_bb0275","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1111\/j.1600-6143.2012.04029.x","article-title":"CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8","volume":"12","author":"Badell","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0280","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1600-6143.2012.04341.x","article-title":"Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy","volume":"13","author":"Lowe","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0285","doi-asserted-by":"crossref","DOI":"10.1111\/xen.12713","article-title":"Anti-thymoglobulin induction improves neonatal porcine xenoislet engraftment and survival","volume":"28","author":"Gao","year":"2021","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.898948","article-title":"Xenotransplantation of genetically modified neonatal pig islets cures diabetes in baboons","volume":"13","author":"Hawthorne","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.trre.2025.100913_bb0295","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1097\/TP.0b013e3181fe1377","article-title":"Islet transplantation in type 1 diabetic patients using calcineurin inhibitor-free immunosuppressive protocols based on T-cell adhesion or costimulation blockade","volume":"90","author":"Posselt","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2025.100913_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11367","article-title":"A multi-modal approach to islet and pancreas transplantation with calcineurin-sparing immunosuppression maintains long-term insulin Independence in patients with type I diabetes","volume":"36","author":"Wisel","year":"2023","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2025.100913_bb0305","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1111\/ajt.12863","article-title":"Conversion from tacrolimus to belatacept to prevent the progression of chronic kidney disease in pancreas transplantation: case report of two patients","volume":"14","author":"Mujtaba","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0310","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1111\/ajt.15817","article-title":"Challenges of calcineurin inhibitor withdrawal following combined pancreas and kidney transplantation: results of a prospective, randomized clinical trial","volume":"20","author":"Stock","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2025.100913_bb0315","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.12628","article-title":"Belatacept rescue therapy in the early period after simultaneous kidney-pancreas transplantation","volume":"37","author":"Esposito","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2025.100913_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.12778","article-title":"Belatacept in pancreas transplantation: promising insights from a cohort series","volume":"37","author":"Masset","year":"2024","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2025.100913_bb0325","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3390\/jcm9113479","article-title":"Opportunistic infections and efficacy following conversion to Belatacept-based therapy after kidney transplantation: a French multicenter cohort","volume":"9","author":"Bertrand","year":"2020","journal-title":"J Clin Med"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X25000138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T22:56:11Z","timestamp":1744325771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X25000138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0955470X25000138"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2025.100913","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transition from preclinical to clinical application of CTLA4-Ig co-stimulation blockage in beta-cell replacement therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2025.100913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100913"}}